Development, Characterization, and In Vivo Evaluation of a Novel Aptamer (Anti-MUC1/Y) for Breast Cancer Therapy.

Khan, Huma; Makwana, Vaidehi; Santos, Sofia Nascimento Dos; Bonacossa de Almeida, Carlos Eduardo; Santos-Oliveira, Ralph; Missailidis, Sotiris

Khan, Huma; Makwana, Vaidehi; Santos, Sofia Nascimento Dos; Bonacossa de Almeida, Carlos Eduardo; Santos-Oliveira, Ralph; Missailidis, Sotiris.

Afiliação

Khan H; Department of Life, Health and Chemical Sciences, Faculty of Science, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK.
Makwana V; Department of Life, Health and Chemical Sciences, Faculty of Science, The Open University, Walton Hall, Milton Keynes MK7 6AA, UK.
Santos SND; Radiopharmacy Department, Nuclear Energy Research Institute, São Paulo 05508-000, Brazil.
Bonacossa de Almeida CE; Division of Medical Physics, Radiation Protection and Dosimetry Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 22783-127, Brazil.
Santos-Oliveira R; Nuclear Engineering Institute, Brazilian Nuclear Energy Commission, Rio de Janeiro 21941-972, Brazil.
Missailidis S; Laboratory of Radiopharmacy and Nanoradiopharmaceuticals, Zona Oeste State University, Rio de Janeiro 23070-200, Brazil.

Pharmaceutics ; 13(8)2021 Aug 11.

Article em En | MEDLINE | ID: mdl-34452200

Palavras-chave

MUC1/Y; aptamer; cancer; pharmacokinetics; therapy

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Pharmaceutics Ano de publicação: 2021 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google